CASPOFUNGIN ACETATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2001)
Entry Type: Small molecule
Molecule Category: Salt
UNII: VUW370O5QE
Parent Compound: CASPOFUNGIN

Structure
InChI Key OGUJBRYAAJYXQP-LLXMLGLCSA-N
Smile CC(=O)O.CC(=O)O.CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O
InChI
InChI=1S/C52H88N10O15.2C2H4O2/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72;2*1-2(3)4/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75);2*1H3,(H,3,4)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+;;/m1../s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C56H96N10O19
Molecular Weight 1213.43
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Pharmacology

Action Mechanism of Action Reference
INHIBITOR 1,3-beta-glucan synthase inhibitor DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Mycoses 4 D009181 ClinicalTrials
Candidiasis, Invasive 3 D058365 ClinicalTrials
Neoplasms 3 D009369 ClinicalTrials

Related Entries

Parent

Side Effects from Label

Side effects Relative Frequency (%) Labels
General disorders and administration site conditions Chills 75.3
Investigations Body temperature increased 69.7
Gastrointestinal disorders Gastrointestinal disorder 55.0
Infections and infestations Infection 54.0
Infections and infestations Infestation 54.0
Respiratory, thoracic and mediastinal disorders Mediastinal disorder 54.0
Gastrointestinal disorders Gastrointestinal disorder 53.0
Gastrointestinal disorders Gastrointestinal disorder 50.0
Gastrointestinal disorders Gastrointestinal disorder 49.0
Respiratory, thoracic and mediastinal disorders Mediastinal disorder 49.0
Infections and infestations Infection 48.0
Infections and infestations Infestation 48.0
Respiratory, thoracic and mediastinal disorders Mediastinal disorder 47.0
Infections and infestations Infection 45.0
Infections and infestations Infestation 45.0
Respiratory, thoracic and mediastinal disorders Mediastinal disorder 43.0
Gastrointestinal disorders Gastrointestinal disorder 42.0
Infections and infestations Infection 42.0
Infections and infestations Infestation 42.0
Skin and subcutaneous tissue disorders Skin disorder 42.0
Gastrointestinal disorders Gastrointestinal disorder 41.0
Skin and subcutaneous tissue disorders Skin disorder 41.0
Infections and infestations Infection 40.0
Infections and infestations Infestation 40.0
Respiratory, thoracic and mediastinal disorders Mediastinal disorder 40.0
Skin and subcutaneous tissue disorders Skin disorder 39.0
Vascular disorders Angiopathy 38.0
Investigations Haemoglobin decreased 37.1
Skin and subcutaneous tissue disorders Skin disorder 37.0
Gastrointestinal disorders Gastrointestinal disorder 35.0
Infections and infestations Infection 35.0
Infections and infestations Infestation 35.0
Cardiac disorders Cardiac disorder 34.0
Investigations Body temperature increased 33.0
Gastrointestinal disorders Gastrointestinal disorder 33.0
Skin and subcutaneous tissue disorders Skin disorder 33.0
Investigations Haematocrit decreased 32.6
Investigations Blood alkaline phosphatase increased 32.0
Investigations Blood potassium decreased 32.0
Respiratory, thoracic and mediastinal disorders Mediastinal disorder 32.0
Investigations Blood potassium decreased 31.5
General disorders and administration site conditions Chills 31.0
Investigations Body temperature increased 30.0
General disorders and administration site conditions Chills 30.0
Gastrointestinal disorders Gastrointestinal disorder 30.0
Infections and infestations Infection 30.0
Infections and infestations Infestation 30.0
Investigations Body temperature increased 29.0
Investigations Body temperature increased 28.6
Investigations Blood creatinine increased 28.1
Investigations Blood creatinine increased 28.0
Skin and subcutaneous tissue disorders Skin disorder 28.0
Investigations Blood potassium decreased 27.0
Investigations Body temperature increased 27.0
Gastrointestinal disorders Diarrhoea 27.0
Respiratory, thoracic and mediastinal disorders Mediastinal disorder 27.0
Nervous system disorders Nervous system disorder 27.0
General disorders and administration site conditions Chills 26.4
Investigations Body temperature increased 26.2
Cardiac disorders Cardiac disorder 26.0
Respiratory, thoracic and mediastinal disorders Mediastinal disorder 26.0
Vascular disorders Angiopathy 25.0
Nervous system disorders Nervous system disorder 25.0
Skin and subcutaneous tissue disorders Skin disorder 25.0
General disorders and administration site conditions Chills 24.7
Vascular disorders Angiopathy 24.0
Metabolism and nutrition disorders Malnutrition 24.0
Investigations Blood potassium decreased 23.4
Investigations Body temperature increased 23.2
Investigations Body temperature increased 23.1
Vascular disorders Angiopathy 23.0
Investigations Blood alkaline phosphatase increased 23.0
Investigations Blood potassium decreased 23.0
Investigations Blood urea increased 23.0
Investigations Body temperature increased 23.0
General disorders and administration site conditions Chills 23.0
Skin and subcutaneous tissue disorders Dermatitis 23.0
Investigations Haemoglobin decreased 23.0
Metabolism and nutrition disorders Malnutrition 23.0
Respiratory, thoracic and mediastinal disorders Mediastinal disorder 23.0
Skin and subcutaneous tissue disorders Rash 23.0
Investigations Alanine aminotransferase increased 22.7
Investigations Aspartate aminotransferase increased 22.7
Investigations Blood creatinine increased 22.6
Investigations Aspartate aminotransferase increased 22.5
Vascular disorders Phlebitis 22.5
Vascular disorders Thrombophlebitis 22.5
Investigations Blood alkaline phosphatase increased 22.0
Metabolism and nutrition disorders Malnutrition 22.0
Investigations Body temperature increased 21.3
Gastrointestinal disorders Nausea 21.3
Vascular disorders Angiopathy 21.0
Investigations Blood alkaline phosphatase increased 21.0
Investigations Body temperature increased 21.0
Investigations Haemoglobin decreased 21.0
Metabolism and nutrition disorders Malnutrition 21.0
Investigations Alanine aminotransferase increased 20.0
Vascular disorders Angiopathy 20.0
Gastrointestinal disorders Diarrhoea 20.0
Vascular disorders Hypotension 20.0
Gastrointestinal disorders Nausea 20.0
Metabolism and nutrition disorders Respiratory failure 20.0
Investigations Body temperature increased 19.4
Investigations Blood alkaline phosphatase increased 19.3
Nervous system disorders Headache 19.1
Vascular disorders Angiopathy 19.0
Investigations Aspartate aminotransferase increased 19.0
Cardiac disorders Cardiac disorder 19.0
Cardiac disorders Tachycardia 19.0
Investigations White blood cell count decreased 19.0
Investigations Alanine aminotransferase increased 18.0
Vascular disorders Angiopathy 18.0
Investigations Blood potassium decreased 18.0
Gastrointestinal disorders Diarrhoea 18.0
Investigations Haematocrit decreased 18.0
Investigations Haemoglobin decreased 18.0
Nervous system disorders Nervous system disorder 18.0
Vascular disorders Phlebitis 18.0
Investigations Alanine aminotransferase increased 17.0
Investigations Aspartate aminotransferase increased 17.0
Investigations Blood alkaline phosphatase increased 17.0
Investigations Blood bilirubin increased 17.0
Investigations Body temperature increased 17.0
Cardiac disorders Cardiac disorder 17.0
Gastrointestinal disorders Diarrhoea 17.0
Gastrointestinal disorders Nausea 17.0
Nervous system disorders Nervous system disorder 17.0
Gastrointestinal disorders Vomiting 17.0
Investigations Alanine aminotransferase increased 16.0
Investigations Aspartate aminotransferase increased 16.0
Cardiac disorders Cardiac disorder 16.0
Skin and subcutaneous tissue disorders Dermatitis 16.0
Gastrointestinal disorders Diarrhoea 16.0
Investigations Haematocrit decreased 16.0
Investigations Haemoglobin decreased 16.0
Vascular disorders Hypotension 16.0
Nervous system disorders Nervous system disorder 16.0
Skin and subcutaneous tissue disorders Rash 16.0
Gastrointestinal disorders Vomiting 16.0
Investigations Blood urea increased 15.8
Vascular disorders Phlebitis 15.7
Vascular disorders Thrombophlebitis 15.7
Investigations Blood alkaline phosphatase increased 15.6
Investigations Alanine aminotransferase increased 15.0
Vascular disorders Angiopathy 15.0
Investigations Blood alkaline phosphatase increased 15.0
Investigations Blood potassium decreased 15.0
Gastrointestinal disorders Diarrhoea 15.0
Nervous system disorders Headache 15.0
Gastrointestinal disorders Nausea 15.0
Skin and subcutaneous tissue disorders Skin disorder 15.0
Investigations Blood albumin decreased 14.9
Investigations Alanine aminotransferase increased 14.0
Investigations Aspartate aminotransferase increased 14.0
Investigations Bilirubin conjugated increased 14.0
Investigations Blood bilirubin increased 14.0
Musculoskeletal and connective tissue disorders Connective tissue disorder 14.0
Skin and subcutaneous tissue disorders Dermatitis 14.0
Gastrointestinal disorders Diarrhoea 14.0
Respiratory, thoracic and mediastinal disorders Pleural effusion 14.0
Skin and subcutaneous tissue disorders Rash 14.0
Infections and infestations Septic shock 14.0
General disorders and administration site conditions Chills 13.8
Vascular disorders Phlebitis 13.8
Vascular disorders Thrombophlebitis 13.8
Gastrointestinal disorders Vomiting 13.5
Investigations Alanine aminotransferase increased 13.0
Investigations Aspartate aminotransferase increased 13.0
Infections and infestations Aspergillus infection 13.0
Investigations Blood alkaline phosphatase increased 13.0
Investigations Blood bilirubin increased 13.0
Investigations Blood potassium decreased 13.0
Investigations Body temperature increased 13.0
Cardiac disorders Cardiac disorder 13.0
General disorders and administration site conditions Chills 13.0
Skin and subcutaneous tissue disorders Dermatitis 13.0
Investigations Haematocrit decreased 13.0
Nervous system disorders Nervous system disorder 13.0
Skin and subcutaneous tissue disorders Rash 13.0
Infections and infestations Septic shock 13.0
Investigations Aspartate aminotransferase increased 12.9
Investigations Haemoglobin decreased 12.3
Gastrointestinal disorders Abdominal pain 12.0
Investigations Alanine aminotransferase increased 12.0
Investigations Aspartate aminotransferase increased 12.0
Investigations Blood alkaline phosphatase increased 12.0
Musculoskeletal and connective tissue disorders Connective tissue disorder 12.0
Gastrointestinal disorders Gastrointestinal pain 12.0
Nervous system disorders Headache 12.0
Vascular disorders Hypotension 12.0
Immune system disorders Immune system disorder 12.0
Cardiac disorders Oedema peripheral 12.0
Metabolism and nutrition disorders Respiratory failure 12.0
Cardiac disorders Tachycardia 12.0
Gastrointestinal disorders Vomiting 12.0
Investigations White blood cell count decreased 12.0
Investigations Alanine aminotransferase increased 11.8
Investigations Blood alkaline phosphatase increased 11.8
Metabolism and nutrition disorders Hypokalaemia 11.8
Investigations Body temperature increased 11.7
Investigations Blood potassium decreased 11.5
Cardiac disorders Tachycardia 11.5
Nervous system disorders Headache 11.3
Gastrointestinal disorders Nausea 11.3
Vascular disorders Phlebitis 11.3
Vascular disorders Thrombophlebitis 11.3
Gastrointestinal disorders Diarrhoea 11.2
Investigations Haematocrit decreased 11.1
Gastrointestinal disorders Abdominal pain 11.0
Blood and lymphatic system disorders Anaemia 11.0
Investigations Blood creatinine increased 11.0
Musculoskeletal and connective tissue disorders Connective tissue disorder 11.0
Respiratory, thoracic and mediastinal disorders Cough 11.0
Gastrointestinal disorders Gastrointestinal pain 11.0
Nervous system disorders Headache 11.0
Metabolism and nutrition disorders Malnutrition 11.0
Gastrointestinal disorders Nausea 11.0
Cardiac disorders Oedema peripheral 11.0
Vascular disorders Phlebitis 11.0
Infections and infestations Pneumonia 11.0
Metabolism and nutrition disorders Respiratory failure 11.0
Infections and infestations Septic shock 11.0
Cardiac disorders Tachycardia 11.0
Respiratory, thoracic and mediastinal disorders Tachypnoea 11.0
Gastrointestinal disorders Vomiting 11.0
Investigations Alanine aminotransferase increased 10.8
Investigations Aspartate aminotransferase increased 10.8
Investigations Blood potassium decreased 10.8
Investigations Alanine aminotransferase increased 10.6
Investigations Blood alkaline phosphatase increased 10.5
Investigations Haemoglobin decreased 10.5
Cardiac disorders Tachycardia 10.4
Respiratory, thoracic and mediastinal disorders Tachypnoea 10.4
Investigations Blood urea increased 10.3
Investigations Blood bilirubin increased 10.0
Investigations Blood urine 10.0
Investigations Blood urine present 10.0
General disorders and administration site conditions Chills 10.0
Respiratory, thoracic and mediastinal disorders Cough 10.0
Skin and subcutaneous tissue disorders Dermatitis 10.0
Gastrointestinal disorders Diarrhoea 10.0
Cardiac disorders Dyspnoea 10.0
Renal and urinary disorders Haematuria 10.0
Vascular disorders Hypertension 10.0
Vascular disorders Hypotension 10.0
General disorders and administration site conditions Mucosal inflammation 10.0
Infections and infestations Pneumonia 10.0
Skin and subcutaneous tissue disorders Rash 10.0
Investigations Blood potassium decreased 9.9
Gastrointestinal disorders Abdominal pain 9.0
Blood and lymphatic system disorders Anaemia 9.0
Investigations Aspartate aminotransferase increased 9.0
Investigations Bilirubin conjugated increased 9.0
Investigations Blood alkaline phosphatase increased 9.0
Investigations Blood glucose increased 9.0
Investigations Blood magnesium decreased 9.0
Investigations Blood potassium decreased 9.0
Investigations Blood urea increased 9.0
General disorders and administration site conditions Chills 9.0
Respiratory, thoracic and mediastinal disorders Cough 9.0
General disorders and administration site conditions Device related infection 9.0
Cardiac disorders Dyspnoea 9.0
Skin and subcutaneous tissue disorders Erythema 9.0
Gastrointestinal disorders Gastrointestinal pain 9.0
Nervous system disorders Headache 9.0
Vascular disorders Hypertension 9.0
Vascular disorders Hypotension 9.0
Gastrointestinal disorders Nausea 9.0
General disorders and administration site conditions Pain 9.0
Respiratory, thoracic and mediastinal disorders Pleural effusion 9.0
Infections and infestations Septic shock 9.0
Cardiac disorders Tachycardia 9.0
Gastrointestinal disorders Vomiting 9.0
Investigations Alanine aminotransferase increased 8.9
Investigations Blood bilirubin increased 8.9
Skin and subcutaneous tissue disorders Dermatitis 8.9
Nervous system disorders Headache 8.9
Skin and subcutaneous tissue disorders Rash 8.9
Investigations Alanine aminotransferase increased 8.7
Investigations Blood albumin decreased 8.6
Gastrointestinal disorders Vomiting 8.6
Investigations White blood cell count decreased 8.6
Vascular disorders Phlebitis 8.5
Vascular disorders Thrombophlebitis 8.5
Investigations Blood bilirubin increased 8.4
Investigations Blood alkaline phosphatase increased 8.3
Investigations Alanine aminotransferase increased 8.1
Blood and lymphatic system disorders Anaemia 8.0
Musculoskeletal and connective tissue disorders Back pain 8.0
Investigations Bilirubin conjugated increased 8.0
Investigations Blood albumin decreased 8.0
Investigations Blood potassium decreased 8.0
Investigations Blood potassium increased 8.0
Investigations Blood urea increased 8.0
General disorders and administration site conditions Chills 8.0
Respiratory, thoracic and mediastinal disorders Cough 8.0
Skin and subcutaneous tissue disorders Dermatitis 8.0
Immune system disorders Graft versus host disease 8.0
Metabolism and nutrition disorders Hypokalaemia 8.0
Vascular disorders Hypotension 8.0
General disorders and administration site conditions Mucosal inflammation 8.0
Gastrointestinal disorders Nausea 8.0
Nervous system disorders Nervous system disorder 8.0
General disorders and administration site conditions Oedema 8.0
Investigations Protein total decreased 8.0
Skin and subcutaneous tissue disorders Pruritus 8.0
Respiratory, thoracic and mediastinal disorders Rales 8.0
Skin and subcutaneous tissue disorders Rash 8.0
Respiratory, thoracic and mediastinal disorders Respiratory distress 8.0
Cardiac disorders Tachycardia 8.0
Gastrointestinal disorders Vomiting 8.0
Skin and subcutaneous tissue disorders Erythema 7.9
Nervous system disorders Tremor 7.9
Investigations White blood cell count decreased 7.9
Investigations Blood alkaline phosphatase increased 7.7
General disorders and administration site conditions Chills 7.7
Nervous system disorders Headache 7.7
Gastrointestinal disorders Vomiting 7.7
Investigations Blood alkaline phosphatase increased 7.69
Investigations Aspartate aminotransferase increased 7.6
Investigations Haematocrit decreased 7.3
Metabolism and nutrition disorders Hypokalaemia 7.3
Gastrointestinal disorders Abdominal pain 7.0
Investigations Alanine aminotransferase increased 7.0
Investigations Aspartate aminotransferase increased 7.0
Investigations Blood albumin decreased 7.0
Investigations Blood alkaline phosphatase increased 7.0
Investigations Blood magnesium decreased 7.0
Investigations Body temperature increased 7.0
Gastrointestinal disorders Diarrhoea 7.0
Gastrointestinal disorders Gastrointestinal pain 7.0
Vascular disorders Hypotension 7.0
Immune system disorders Immune system disorder 7.0
Gastrointestinal disorders Nausea 7.0
Infections and infestations Pneumonia 7.0
Skin and subcutaneous tissue disorders Pruritus 7.0
Respiratory, thoracic and mediastinal disorders Rales 7.0
Infections and infestations Sepsis 7.0
Cardiac disorders Tachycardia 7.0
Investigations Blood alkaline phosphatase increased 6.9
General disorders and administration site conditions Asthenia 6.7
General disorders and administration site conditions Fatigue 6.7
General disorders and administration site conditions Induration 6.7
Investigations Blood bicarbonate decreased 6.6
Investigations Alanine aminotransferase increased 6.5
Vascular disorders Hypertension 6.4
Gastrointestinal disorders Nausea 6.4
Investigations Bilirubin conjugated increased 6.3
Skin and subcutaneous tissue disorders Dermatitis 6.2
Skin and subcutaneous tissue disorders Rash 6.2
Investigations White blood cell count decreased 6.2
Investigations Aspartate aminotransferase increased 6.0
Investigations Blood glucose increased 6.0
Investigations Blood potassium decreased 6.0
Investigations Body temperature increased 6.0
Respiratory, thoracic and mediastinal disorders Cough 6.0
Skin and subcutaneous tissue disorders Dermatitis 6.0
Gastrointestinal disorders Diarrhoea 6.0
Nervous system disorders Headache 6.0
Vascular disorders Hypertension 6.0
Metabolism and nutrition disorders Hypokalaemia 6.0
Vascular disorders Hypotension 6.0
General disorders and administration site conditions Mucosal inflammation 6.0
Gastrointestinal disorders Nausea 6.0
Skin and subcutaneous tissue disorders Pruritus 6.0
Skin and subcutaneous tissue disorders Rash 6.0
Metabolism and nutrition disorders Respiratory failure 6.0
Gastrointestinal disorders Vomiting 6.0
Nervous system disorders Headache 5.7
General disorders and administration site conditions Discomfort 5.6
General disorders and administration site conditions Feeling abnormal 5.6
Metabolism and nutrition disorders Hypokalaemia 5.6
General disorders and administration site conditions Ill-defined disorder 5.6
General disorders and administration site conditions Malaise 5.6
Gastrointestinal disorders Nausea 5.6
General disorders and administration site conditions Oedema 5.6
General disorders and administration site conditions Pain 5.6
Renal and urinary disorders Renal failure 5.6
Renal and urinary disorders Renal impairment 5.6
General disorders and administration site conditions Swelling 5.6
Investigations Blood creatinine increased 5.5
Investigations Blood albumin decreased 5.4
Investigations Haematocrit decreased 5.4
Investigations Haemoglobin decreased 5.4
General disorders and administration site conditions Chills 5.3
Skin and subcutaneous tissue disorders Dermatitis 5.3
Skin and subcutaneous tissue disorders Rash 5.3
Investigations Blood bilirubin increased 5.2
Investigations Alanine aminotransferase increased 5.0
Investigations Bilirubin conjugated increased 5.0
Skin and subcutaneous tissue disorders Decubitus ulcer 5.0
Nervous system disorders Headache 5.0
Vascular disorders Hypertension 5.0
Metabolism and nutrition disorders Hypokalaemia 5.0
Gastrointestinal disorders Nausea 5.0
Infections and infestations Pneumonia 5.0
Infections and infestations Sepsis 5.0
Investigations Protein urine present 4.9
Vascular disorders Phlebitis 4.8
Vascular disorders Thrombophlebitis 4.8
Skin and subcutaneous tissue disorders Dermatitis 4.7
Skin and subcutaneous tissue disorders Rash 4.7
Investigations Blood albumin decreased 4.6
Skin and subcutaneous tissue disorders Dermatitis 4.6
General disorders and administration site conditions Pain 4.6
Skin and subcutaneous tissue disorders Rash 4.6
Investigations White blood cell count decreased 4.6
Investigations Blood bilirubin increased 4.5
General disorders and administration site conditions Pain 4.5
Investigations Protein urine present 4.5
Cardiac disorders Tachycardia 4.5
Respiratory, thoracic and mediastinal disorders Tachypnoea 4.5
Investigations Blood potassium decreased 4.3
Nervous system disorders Headache 4.3
Cardiac disorders Dyspnoea 4.2
General disorders and administration site conditions Flushing 4.2
Metabolism and nutrition disorders Hypokalaemia 4.2
Gastrointestinal disorders Abdominal pain 4.0
Investigations Alanine aminotransferase increased 4.0
Investigations Aspartate aminotransferase increased 4.0
Musculoskeletal and connective tissue disorders Back pain 4.0
Investigations Blood bilirubin increased 4.0
Investigations Blood urea increased 4.0
Skin and subcutaneous tissue disorders Dermatitis 4.0
Skin and subcutaneous tissue disorders Erythema 4.0
Gastrointestinal disorders Gastrointestinal pain 4.0
Immune system disorders Graft versus host disease 4.0
Renal and urinary disorders Haematuria 4.0
Nervous system disorders Headache 4.0
Vascular disorders Hypertension 4.0
Metabolism and nutrition disorders Hypokalaemia 4.0
General disorders and administration site conditions Mucosal inflammation 4.0
Gastrointestinal disorders Nausea 4.0
General disorders and administration site conditions Oedema 4.0
Infections and infestations Pneumonia 4.0
Skin and subcutaneous tissue disorders Rash 4.0
Respiratory, thoracic and mediastinal disorders Respiratory distress 4.0
Cardiac disorders Tachycardia 4.0
Blood and lymphatic system disorders Anaemia 3.8
Immune system disorders Angioedema 3.8
Investigations Blood bilirubin increased 3.8
Immune system disorders Circumoral oedema 3.8
Cardiac disorders Dyspnoea 3.8
Hepatobiliary disorders Hepatitis 3.8
Blood and lymphatic system disorders Hyperbilirubinaemia 3.8
Metabolism and nutrition disorders Hypokalaemia 3.8
Metabolism and nutrition disorders Hyponatraemia 3.8
Vascular disorders Hypotension 3.8
General disorders and administration site conditions Injection site phlebitis 3.8
Blood and lymphatic system disorders Jaundice 3.8
Respiratory, thoracic and mediastinal disorders Laryngospasm 3.8
Gastrointestinal disorders Nausea 3.8
Investigations Alanine aminotransferase increased 3.7
Investigations Blood creatinine increased 3.7
Investigations Blood potassium decreased 3.7
Metabolism and nutrition disorders Hypokalaemia 3.7
Investigations Protein urine present 3.7
Investigations Blood bicarbonate decreased 3.6
Investigations Blood potassium decreased 3.6
Investigations Body temperature increased 3.6
General disorders and administration site conditions Catheter site pain 3.6
Gastrointestinal disorders Diarrhoea 3.6
General disorders and administration site conditions Flushing 3.6
Vascular disorders Hypotension 3.6
General disorders and administration site conditions Pain 3.6
Investigations pH urine increased 3.6
Skin and subcutaneous tissue disorders Pruritus 3.6
Investigations Blood potassium decreased 3.5
Gastrointestinal disorders Nausea 3.5
Vascular disorders Phlebitis 3.5
Vascular disorders Thrombophlebitis 3.5
Gastrointestinal disorders Vomiting 3.5
Investigations Blood uric acid increased 3.4
General disorders and administration site conditions Decreased appetite 3.4
Skin and subcutaneous tissue disorders Dermatitis 3.4
General disorders and administration site conditions Hyperhidrosis 3.4
Investigations Platelet count decreased 3.4
Investigations Protein total decreased 3.4
Skin and subcutaneous tissue disorders Rash 3.4
Immune system disorders Vasculitis 3.4
Investigations Blood bilirubin increased 3.3
Investigations Protein urine present 3.3
Investigations Blood bilirubin increased 3.2
Investigations Blood calcium decreased 3.2
Skin and subcutaneous tissue disorders Dermatitis 3.2
Blood and lymphatic system disorders Eosinophilia 3.2
General disorders and administration site conditions Hyperhidrosis 3.2
Metabolism and nutrition disorders Hyponatraemia 3.2
Blood and lymphatic system disorders Jaundice 3.2
Blood and lymphatic system disorders Neutropenia 3.2
Investigations Protein total decreased 3.2
Skin and subcutaneous tissue disorders Rash 3.2
Gastrointestinal disorders Vomiting 3.2
Gastrointestinal disorders Diarrhoea 3.1
Blood and lymphatic system disorders Eosinophilia 3.1
Investigations Haemoglobin decreased 3.1
General disorders and administration site conditions Induration 3.1
General disorders and administration site conditions Influenza like illness 3.1
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 3.1
Musculoskeletal and connective tissue disorders Myalgia 3.1
Gastrointestinal disorders Nausea 3.1
Blood and lymphatic system disorders Neutropenia 3.1
General disorders and administration site conditions Oedema 3.1
Nervous system disorders Paraesthesia 3.1
Investigations Platelet count decreased 3.1
Investigations Protein total decreased 3.1
Gastrointestinal disorders Vomiting 3.1
Blood and lymphatic system disorders Eosinophilia 3.08
Investigations Haemoglobin decreased 3.08
Blood and lymphatic system disorders Neutropenia 3.08
Blood and lymphatic system disorders Eosinophilia 3.07
Investigations Protein total decreased 3.07
Investigations Blood bilirubin increased 3.0
Investigations Blood creatinine increased 3.0
Investigations Blood potassium increased 3.0
Skin and subcutaneous tissue disorders Decubitus ulcer 3.0
Vascular disorders Hypotension 3.0
General disorders and administration site conditions Oedema 3.0
Investigations Blood alkaline phosphatase increased 2.9
Investigations Blood potassium decreased 2.9
Investigations Body temperature increased 2.9
General disorders and administration site conditions Flushing 2.9
Nervous system disorders Headache 2.9
Gastrointestinal disorders Nausea 2.9
Gastrointestinal disorders Vomiting 2.9
Investigations Blood bilirubin increased 2.8
General disorders and administration site conditions Hyperhidrosis 2.8
Musculoskeletal and connective tissue disorders Back pain 2.7
Investigations Blood phosphorus increased 2.7
Gastrointestinal disorders Diarrhoea 2.7
Investigations Blood bilirubin increased 2.6
Gastrointestinal disorders Diarrhoea 2.6
Metabolism and nutrition disorders Hypomagnesaemia 2.6
Investigations Blood bilirubin increased 2.5
General disorders and administration site conditions Chills 2.5
Gastrointestinal disorders Nausea 2.5
General disorders and administration site conditions Pain 2.5
Skin and subcutaneous tissue disorders Pruritus 2.5
Gastrointestinal disorders Abdominal pain 2.4
Investigations Blood potassium increased 2.4
Gastrointestinal disorders Diarrhoea 2.4
Skin and subcutaneous tissue disorders Erythema 2.4
Gastrointestinal disorders Gastrointestinal pain 2.4
Vascular disorders Hypotension 2.4
Cardiac disorders Tachycardia 2.4
Nervous system disorders Tremor 2.4
Metabolism and nutrition disorders Hypomagnesaemia 2.3
Investigations Prothrombin level increased 2.3
Immune system disorders Anaphylactic shock 2.2
Investigations Blood creatinine increased 2.2
Investigations Blood potassium increased 2.2
General disorders and administration site conditions Hyperhidrosis 2.2
Nervous system disorders Insomnia 2.2
Investigations Lymphocyte count increased 2.2
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 2.2
Musculoskeletal and connective tissue disorders Myalgia 2.2
General disorders and administration site conditions Pain 2.2
Investigations Platelet count decreased 2.2
Cardiac disorders Dizziness 2.13
Investigations Platelet count decreased 2.13
Gastrointestinal disorders Diarrhoea 2.1
Cardiac disorders Dizziness 2.1
Gastrointestinal disorders Gastritis 2.1
General disorders and administration site conditions Pain 2.1
Investigations Alanine aminotransferase increased 2.0
Blood and lymphatic system disorders Anaemia 2.0
Investigations Aspartate aminotransferase increased 2.0
Investigations Blood alkaline phosphatase increased 2.0
Investigations Blood phosphorus decreased 2.0
Cardiac disorders Dyspnoea 2.0
Nervous system disorders Headache 2.0
Vascular disorders Hypertension 2.0
Metabolism and nutrition disorders Hypokalaemia 2.0
General disorders and administration site conditions Injection site erythema 2.0
General disorders and administration site conditions Injection site phlebitis 2.0
General disorders and administration site conditions Injection site swelling 2.0
Metabolism and nutrition disorders Malnutrition 2.0
Nervous system disorders Nervous system disorder 2.0
Metabolism and nutrition disorders Respiratory failure 2.0
Respiratory, thoracic and mediastinal disorders Tachypnoea 2.0
Investigations Aspartate aminotransferase increased 1.9
Investigations Blood calcium decreased 1.9
Investigations Blood urea increased 1.9
Metabolism and nutrition disorders Hyponatraemia 1.9
Metabolism and nutrition disorders Malnutrition 1.9
Blood and lymphatic system disorders Neutropenia 1.9
Investigations Blood bilirubin increased 1.8
Investigations Blood phosphorus decreased 1.8
General disorders and administration site conditions Chills 1.8
General disorders and administration site conditions Flushing 1.8
Vascular disorders Hypertension 1.8
Vascular disorders Hypotension 1.8
Gastrointestinal disorders Nausea 1.8
Skin and subcutaneous tissue disorders Pruritus 1.8
Cardiac disorders Tachycardia 1.8
Nervous system disorders Tremor 1.8
Gastrointestinal disorders Vomiting 1.8
Investigations Lymphocyte count increased 1.6
Investigations Haematocrit decreased 1.54
Investigations Blood creatinine increased 1.5
General disorders and administration site conditions Chills 1.5
Cardiac disorders Dizziness 1.5
Skin and subcutaneous tissue disorders Erythema 1.5
Investigations Haematocrit decreased 1.5
Metabolism and nutrition disorders Hyponatraemia 1.5
Investigations Platelet count decreased 1.5
Investigations Prothrombin level increased 1.5
Skin and subcutaneous tissue disorders Pruritus 1.5
Gastrointestinal disorders Abdominal pain 1.4
Gastrointestinal disorders Gastrointestinal pain 1.4
Cardiac disorders Tachycardia 1.4
General disorders and administration site conditions Decreased appetite 1.3
Skin and subcutaneous tissue disorders Dermatitis 1.3
Gastrointestinal disorders Diarrhoea 1.3
Skin and subcutaneous tissue disorders Erythema 1.3
General disorders and administration site conditions Hyperhidrosis 1.3
General disorders and administration site conditions Pain 1.3
Nervous system disorders Paraesthesia 1.3
Investigations Prothrombin level increased 1.3
Skin and subcutaneous tissue disorders Rash 1.3
Cardiac disorders Tachycardia 1.3
Respiratory, thoracic and mediastinal disorders Tachypnoea 1.3
Gastrointestinal disorders Vomiting 1.3
Investigations Blood creatinine increased 1.2
Investigations Blood urea increased 1.2
General disorders and administration site conditions Catheter site pain 1.2
Skin and subcutaneous tissue disorders Erythema 1.2
Nervous system disorders Insomnia 1.2
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 1.2
Musculoskeletal and connective tissue disorders Myalgia 1.2
Investigations Protein urine present 1.2
Skin and subcutaneous tissue disorders Pruritus 1.2
Cardiac disorders Tachycardia 1.2
Gastrointestinal disorders Vomiting 1.2
Investigations Blood calcium decreased 1.1
Investigations Blood potassium increased 1.1
Investigations Body temperature increased 1.1
Cardiac disorders Dizziness 1.1
Blood and lymphatic system disorders Eosinophilia 1.1
Nervous system disorders Headache 1.1
Vascular disorders Hypertension 1.1
Metabolism and nutrition disorders Hyponatraemia 1.1
Blood and lymphatic system disorders Neutropenia 1.1
Nervous system disorders Paraesthesia 1.1
General disorders and administration site conditions Device related infection 1.0
Immune system disorders Graft versus host disease 1.0
Metabolism and nutrition disorders Hypokalaemia 1.0
General disorders and administration site conditions Injection site swelling 1.0
Respiratory, thoracic and mediastinal disorders Tachypnoea 1.0
Investigations Blood bicarbonate decreased 0.9
Investigations Blood potassium increased 0.9
Skin and subcutaneous tissue disorders Dermatitis 0.9
Investigations Haematocrit decreased 0.9
Investigations Haemoglobin decreased 0.9
General disorders and administration site conditions Hyperhidrosis 0.9
Metabolism and nutrition disorders Hypokalaemia 0.9
Vascular disorders Hypotension 0.9
Blood and lymphatic system disorders Jaundice 0.9
Skin and subcutaneous tissue disorders Rash 0.9
Renal and urinary disorders Renal failure 0.9
Renal and urinary disorders Renal impairment 0.9
Gastrointestinal disorders Diarrhoea 0.8
Investigations pH urine increased 0.8
Musculoskeletal and connective tissue disorders Back pain 0.7
Investigations Blood bilirubin increased 0.6
Investigations Blood potassium increased 0.6
Investigations Blood uric acid increased 0.6
Metabolism and nutrition disorders Hypokalaemia 0.6
Gastrointestinal disorders Vomiting 0.6
Respiratory, thoracic and mediastinal disorders Tachypnoea 0.4

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
16.16
Infections and infestations
13.61
Investigations
12.21
Respiratory, thoracic and mediastinal disorders
8.84
Blood and lymphatic system disorders
6.52
Vascular disorders
5.14
Hepatobiliary disorders
4.92
Injury, poisoning and procedural complications
4.58
Skin and subcutaneous tissue disorders
4.08
Metabolism and nutrition disorders
3.84
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
3.52
Gastrointestinal disorders
3.05
Immune system disorders
3.0
Nervous system disorders
2.96
Cardiac disorders
2.23

Cross References

Resources Reference
ChEBI 59900
ChEMBL CHEMBL4297142
FDA SRS VUW370O5QE
PubChem 16119813
SureChEMBL SCHEMBL149293
CONTENTS